Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256630 · ClinicalTrials.gov registry record
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A clinical trial, sponsored by Genomic Health®.
- Terminated
- Registry status
- 128
- Enrollment target
NCT03256630: Clinical Trial study, sponsored by Genomic Health®.
NCT03256630 is a clinical trial that was terminated before completion, run by Genomic Health®. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03256630 was terminated before completion, sponsored by Genomic Health®.
- TERMINATED
- Registry status
- 128 participants
- Enrollment target
Study Summary
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2018-01-10 |
| Est. Completion | 2019-02-28 |
Why NCT03256630 stopped before completion
NCT03256630 is an observational study that tracks outcomes without assigning an intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03256630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03256630 about?
NCT03256630 is a clinical study titled "Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer". A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
What is the current status of trial NCT03256630?
This trial is currently terminated. The enrollment target is 128 participants. The study started on 2018-01-10. Estimated completion is 2019-02-28.
Who is sponsoring clinical trial NCT03256630?
This trial is sponsored by Genomic Health®, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI